Document Detail


Risks of less common cancers in proven mutation carriers with lynch syndrome.
MedLine Citation:
PMID:  23091106     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: Patients with Lynch syndrome are at high risk for colon and endometrial cancer, but also at an elevated risk for other less common cancers. The purpose of this retrospective cohort study was to provide risk estimates for these less common cancers in proven carriers of pathogenic mutations in the mismatch repair (MMR) genes MLH1, MSH2, and MSH6.
PATIENTS AND METHODS: Data were pooled from the German and Dutch national Lynch syndrome registries. Seven different cancer types were analyzed: stomach, small bowel, urinary bladder, other urothelial, breast, ovarian, and prostate cancer. Age-, sex- and MMR gene-specific cumulative risks (CRs) were calculated using the Kaplan-Meier method. Sex-specific incidence rates were compared with general population incidence rates by calculating standardized incidence ratios (SIRs). Multivariate Cox regression analysis was used to estimate the impact of sex and mutated gene on cancer risk.
RESULTS: The cohort comprised 2,118 MMR gene mutation carriers (MLH1, n = 806; MSH2, n = 1,004; MSH6, n = 308). All cancers were significantly more frequent than in the general population. The highest risks were found for male small bowel cancer (SIR, 251; 95% CI, 177 to 346; CR at 70 years, 12.0; 95% CI, 5.7 to 18.2). Breast cancer showed an SIR of 1.9 (95% CI, 1.4 to 2.4) and a CR of 14.4 (95% CI, 9.5 to 19.3). MSH2 mutation carriers had a considerably higher risk of developing urothelial cancer than MLH1 or MSH6 carriers.
CONCLUSION: The sex- and gene-specific differences of less common cancer risks should be taken into account in cancer surveillance and prevention programs for patients with Lynch syndrome.
Authors:
Christoph Engel; Markus Loeffler; Verena Steinke; Nils Rahner; Elke Holinski-Feder; Wolfgang Dietmaier; Hans K Schackert; Heike Goergens; Magnus von Knebel Doeberitz; Timm O Goecke; Wolff Schmiegel; Reinhard Buettner; Gabriela Moeslein; Tom G W Letteboer; Encarna Gómez García; Frederik J Hes; Nicoline Hoogerbrugge; Fred H Menko; Theo A M van Os; Rolf H Sijmons; Anja Wagner; Irma Kluijt; Peter Propping; Hans F A Vasen
Related Documents :
23409916 - Alcohol-attributable cancer deaths and years of potential life lost in the united states.
24474656 - Insurance status and distant-stage disease at diagnosis among adolescent and young adul...
24556086 - Guidelines for surveillance of individuals with constitutional mismatch repair-deficien...
24310616 - Prevalence of the hoxb13 g84e mutation among unaffected men with a family history of pr...
2661486 - Cancer of the esophagus: the wayne state university experience.
16737666 - Can manual treatment of lymphedema promote metastasis?
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-10-22
Journal Detail:
Title:  Journal of clinical oncology : official journal of the American Society of Clinical Oncology     Volume:  30     ISSN:  1527-7755     ISO Abbreviation:  J. Clin. Oncol.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-11     Completed Date:  2013-05-06     Revised Date:  2013-07-30    
Medline Journal Info:
Nlm Unique ID:  8309333     Medline TA:  J Clin Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  4409-15     Citation Subset:  IM    
Affiliation:
University of Leipzig, Leipzig, Germany. christoph.engel@imise.uni-leipzig.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adaptor Proteins, Signal Transducing / genetics
Adult
Aged
Cohort Studies
Colorectal Neoplasms, Hereditary Nonpolyposis / epidemiology*,  genetics*
DNA-Binding Proteins / genetics
Female
Germany / epidemiology
Humans
Male
Middle Aged
MutS Homolog 2 Protein / genetics
Mutation
Neoplasms / epidemiology*,  genetics*
Netherlands / epidemiology
Nuclear Proteins / genetics
Registries
Retrospective Studies
Risk Factors
Chemical
Reg. No./Substance:
0/Adaptor Proteins, Signal Transducing; 0/DNA-Binding Proteins; 0/G-T mismatch-binding protein; 0/MLH1 protein, human; 0/Nuclear Proteins; EC 3.6.1.3/MSH2 protein, human; EC 3.6.1.3/MutS Homolog 2 Protein
Comments/Corrections
Comment In:
J Clin Oncol. 2013 Jun 10;31(17):2229-30   [PMID:  23630212 ]
J Clin Oncol. 2013 Jun 10;31(17):2230

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light...
Next Document:  Research participants' high expectations of benefit in early-phase oncology trials: are we asking th...